SIOX / Sio Gene Terminates Parkinson's Gene Therapy Pact With Oxford Biomedica, Announces CEO Transition

Sio Gene Therapies Inc (NASDAQ: SIOX) will terminate its licensing agreement with the University of Massachusetts to develop and commercialize gene more_horizontal

NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing more_horizontal

NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing more_horizontal

NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing more_horizontal

Sio Gene Therapies Inc  SIOX has decided to terminate its licensing agreement with Oxford Biomedica for AXO-Lenti-PD, its lentiviral gene therapy more_horizontal

Sio Gene Therapies Inc  SIOX has decided to terminate its licensing agreement with Oxford Biomedica for AXO-Lenti-PD, its lentiviral gene therapy more_horizontal

Sio Gene Therapies Inc  SIOX has decided to terminate its licensing agreement with Oxford Biomedica for AXO-Lenti-PD, its lentiviral gene therapy more_horizontal

Are these 'must watch' penny stocks on your list right now? The post 3 ‘Must Watch' Penny Stocks For Your Watchlist Right Now appeared first on Penn more_horizontal